KRAS and neoplasm: At month 14, after five months of radiotherapy, a last mastectomy was performed and a recurrence sample was obtained, which showed a composition of the altered driver genes very similar to those detected in the primary tumour 1, including the EP300 and TP53 mutations, and amplifications in MCL1, CCND1, MDM4, IGF1R, MYC, AKT3, CDK6, JAK2, KRAS.